Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

By sjmartinez • January 27, 2023

Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2022 Dec 14;67:94-101. doi: 10.1016/j.breast.2022.12.003. Epub ahead of print. PMID: 36702070.

Tags: breast cancer, Diarrhea prophylaxis, Dose escalation, early stage, health-related quality of life, Hematology/Oncology, HER2-positive, Neratinib, Publications, Tyrosine kinase inhibitor

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm

Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That[...]

PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma

Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.[...]

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases

Juarez Casillas JE, Nezafat M, Benitez CM, Rzechowski K, Kane N, Sjöstrand K, Anand A, Sonni I, Berenji GR, Duriseti S, Rettig MB, Nickols NG.[...]